

Precision Oncology & Cancer Immunotherapy Market Forecasts to 2034 – Global Analysis By Therapy Type (Immune Checkpoint Inhibitors, CAR-T Cell Therapy, Cancer Vaccines, Monoclonal Antibodies, Targeted Small Molecule Therapy and Other Therapy Types), Biomarker, Cancer Type, Technology, End User and By Geography

<https://marketpublishers.com/r/PDEF7190BA93EN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: PDEF7190BA93EN

Abstracts

According to Statistics MRC, the Global Precision Oncology & Cancer Immunotherapy Market is accounted for \$131.06 billion in 2026 and is expected to reach \$295.58 billion by 2034 growing at a CAGR of 10.7% during the forecast period. Precision oncology and cancer immunotherapy are advanced approaches in oncology that focus on personalized and immune-based cancer treatment. Precision oncology uses genomic profiling and biomarkers to tailor therapies to the specific molecular characteristics of a patient's tumor, improving treatment effectiveness and minimizing side effects. Cancer immunotherapy, including immune checkpoint inhibitors and cell-based therapies, stimulates the body's immune system to recognize and destroy cancer cells. Together, these approaches enhance clinical outcomes, enable targeted interventions, and represent a shift toward individualized, biology-driven cancer care, improving survival rates and transforming treatment strategies across various malignancies.

Market Dynamics:

Driver:

Rising cancer prevalence globally

Increasing incidence of cancers such as lung, breast, and colorectal is creating urgent demand for advanced treatment options. Personalized therapies allow clinicians to tailor interventions based on genetic, molecular, and immunological profiles, improving efficacy and reducing side effects. Immunotherapy approaches, including checkpoint

inhibitors and CAR-T therapies, are gaining traction as they offer durable responses in patients resistant to conventional treatments. The growing burden of cancer worldwide has accelerated investments in precision medicine and biomarker-driven research. Healthcare systems are prioritizing personalized oncology to improve survival rates and reduce healthcare costs.

Restraint:

High cost of personalized treatments

Precision oncology and immunotherapy often involve complex diagnostic tests, advanced biologics, and customized treatment regimens, all of which drive up expenses. Many healthcare systems, particularly in developing regions, struggle to provide widespread access due to limited reimbursement frameworks. Patients face financial toxicity, with out-of-pocket costs becoming a barrier to adoption.

Pharmaceutical companies are under pressure to balance innovation with affordability, but pricing remains a challenge. While ongoing research aims to reduce costs through scalable manufacturing and improved diagnostics, affordability issues persist.

Opportunity:

Development of targeted immunotherapies

Advances in genomics and proteomics are enabling the identification of novel biomarkers and therapeutic targets. Immunotherapies such as monoclonal antibodies, cancer vaccines, and engineered T-cell therapies are increasingly being tailored to individual patient profiles. These approaches offer improved efficacy and reduced toxicity compared to traditional chemotherapy. Pharmaceutical companies are investing heavily in R&D collaborations to accelerate innovation in this space. Regulatory agencies are also supporting fast-track approvals for breakthrough therapies, enhancing market potential.

Threat:

Competition from conventional cancer therapies

Chemotherapy, radiation, and surgery remain the standard of care in many regions due to their established efficacy and lower costs. Physicians and patients may be hesitant to adopt newer, more expensive personalized treatments without long-term evidence of superiority. In resource-constrained settings, conventional therapies continue to dominate due to affordability and accessibility. This entrenched reliance on traditional approaches can slow the uptake of personalized oncology solutions. Overcoming this threat requires robust clinical data, cost-effectiveness studies, and greater awareness among healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the personalized oncology and immunotherapy market. On one hand, disruptions in clinical trials and supply chains delayed the development and delivery of new therapies. Many cancer patients

experienced treatment interruptions due to hospital resource constraints. On the other hand, the pandemic accelerated adoption of digital health and telemedicine, supporting remote patient monitoring and personalized care delivery. Pharmaceutical companies adapted by leveraging decentralized trials and digital platforms to continue research. Post-pandemic recovery has reignited investments in oncology R&D, with personalized immunotherapies regaining momentum.

The lung cancer segment is expected to be the largest during the forecast period. The lung cancer segment is expected to account for the largest market share during the forecast period as rising cancer prevalence globally has made lung cancer one of the most urgent areas for personalized treatment development. Lung cancer remains the leading cause of cancer-related deaths worldwide, driving demand for innovative therapies. Personalized approaches, including biomarker-driven targeted therapies and immunotherapies, are increasingly being adopted to improve survival rates. Advances in diagnostics such as liquid biopsies and genomic sequencing are enhancing early detection and treatment personalization. Pharmaceutical companies are focusing heavily on lung cancer pipelines due to its high clinical and economic burden.

The cancer research institutes segment is expected to have the highest CAGR during the forecast period.

Over the forecast period, the cancer research institutes segment is predicted to witness the highest growth rate due to rising cancer prevalence globally, which has intensified demand for advanced research and innovation in personalized therapies. Institutes are leading efforts in biomarker discovery, immunotherapy development, and precision diagnostics. Collaborations with pharmaceutical companies and government agencies are accelerating clinical trial activity. Research institutes also play a critical role in training oncologists and disseminating knowledge about personalized treatment approaches. As cancer prevalence rises, research institutes will remain at the forefront of innovation, driving rapid growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and rising cancer prevalence globally, which has heightened demand for personalized oncology solutions. The U.S. leads in adoption of precision medicine, supported by strong R&D investments and favorable reimbursement policies. Major pharmaceutical companies and research institutes are headquartered in the region, driving innovation. Regulatory agencies such as the FDA provide fast-track approvals for breakthrough therapies, further boosting adoption. The region's dominance is expected to persist, supported by ongoing innovation and strong healthcare spending.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest

CAGR driven by rapid healthcare digitization and rising cancer prevalence globally, particularly in emerging economies. Countries such as China, India, and Japan are witnessing increasing cancer incidence, creating urgent demand for personalized therapies. Governments are investing in oncology infrastructure and supporting clinical research initiatives. Growing collaborations between local institutes and global pharmaceutical companies are accelerating innovation. Rising disposable incomes and improving healthcare access are expanding patient adoption of advanced treatments. The region also benefits from increasing awareness of precision medicine and immunotherapy.

Key players in the market

Some of the key players in Precision Oncology & Cancer Immunotherapy Market include Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals, BeiGene Ltd., Moderna Inc., BioNTech SE, Iovance Biotherapeutics, Bluebird Bio Inc. and Kite Pharma.

Key Developments:

In March 2026, Johnson & Johnson's Janssen unit introduced a personalized immunotherapy platform combining tumor-infiltrating lymphocytes (TILs) with AI-driven patient selection. The therapy targets advanced ovarian cancer, offering tailored immune responses. J&J's innovation reinforces its commitment to precision oncology, integrating cell therapy with digital health tools for improved patient outcomes.

In February 2026, Roche advanced its personalized oncology portfolio by launching a next-generation companion diagnostic platform integrated with its immunotherapy pipeline. The system enables real-time biomarker profiling for individualized treatment selection in breast and lung cancers. Roche's expansion into AI-driven diagnostics strengthens its leadership in precision oncology, aligning with its strategy to deliver tailored immunotherapy solutions across global markets.

In June 2025, Bristol-Myers Squibb expanded its immuno-oncology franchise with FDA approval of a novel PD-1 inhibitor combination therapy for advanced melanoma. The therapy leverages biomarker-driven patient stratification, enhancing survival outcomes. BMS continues to invest in personalized immunotherapy approaches, reinforcing its competitive edge in checkpoint inhibitor markets and broadening its reach in precision cancer care.

Therapy Types Covered:

Immune Checkpoint Inhibitors

CAR-T Cell Therapy

Cancer Vaccines

Monoclonal Antibodies

Targeted Small Molecule Therapy

Other Therapy Types

Biomarkers Covered:

Genomic Biomarkers

Proteomic Biomarkers

Tumor Mutational Burden (TMB)

PD-L1 Expression

Other Biomarkers

Cancer Types Covered:

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Hematologic Cancers

Other Cancer Types

Technologies Covered:

Next-Generation Sequencing (NGS)

PCR-Based Testing

Flow Cytometry

Gene Editing Technologies

Other Technologies

End Users Covered:

Hospitals

Cancer Research Institutes

Specialty Oncology Clinics

Diagnostic Laboratories

Other End Users

Regions Covered:

North America

United States

Canada

Mexico

Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

Belgium

Sweden

Switzerland

Poland

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Thailand

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

Rest of the World (RoW)

Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

Africa

South Africa

Egypt

Morocco

Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as

per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

- 1.1 Market Snapshot and Key Highlights
- 1.2 Growth Drivers, Challenges, and Opportunities
- 1.3 Competitive Landscape Overview
- 1.4 Strategic Insights and Recommendations

2 RESEARCH FRAMEWORK

- 2.1 Study Objectives and Scope
- 2.2 Stakeholder Analysis
- 2.3 Research Assumptions and Limitations
- 2.4 Research Methodology
 - 2.4.1 Data Collection (Primary and Secondary)
 - 2.4.2 Data Modeling and Estimation Techniques
 - 2.4.3 Data Validation and Triangulation
 - 2.4.4 Analytical and Forecasting Approach

3 MARKET DYNAMICS AND TREND ANALYSIS

- 3.1 Market Definition and Structure
- 3.2 Key Market Drivers
- 3.3 Market Restraints and Challenges
- 3.4 Growth Opportunities and Investment Hotspots
- 3.5 Industry Threats and Risk Assessment
- 3.6 Technology and Innovation Landscape
- 3.7 Emerging and High-Growth Markets
- 3.8 Regulatory and Policy Environment
- 3.9 Impact of COVID-19 and Recovery Outlook

4 COMPETITIVE AND STRATEGIC ASSESSMENT

- 4.1 Porter's Five Forces Analysis
 - 4.1.1 Supplier Bargaining Power
 - 4.1.2 Buyer Bargaining Power
 - 4.1.3 Threat of Substitutes
 - 4.1.4 Threat of New Entrants

- 4.1.5 Competitive Rivalry
- 4.2 Market Share Analysis of Key Players
- 4.3 Product Benchmarking and Performance Comparison

5 GLOBAL PRECISION ONCOLOGY & CANCER IMMUNOTHERAPY MARKET, BY THERAPY TYPE

- 5.1 Immune Checkpoint Inhibitors
- 5.2 CAR-T Cell Therapy
- 5.3 Cancer Vaccines
- 5.4 Monoclonal Antibodies
- 5.5 Targeted Small Molecule Therapy
- 5.6 Other Therapy Types

6 GLOBAL PRECISION ONCOLOGY & CANCER IMMUNOTHERAPY MARKET, BY BIOMARKER

- 6.1 Genomic Biomarkers
- 6.2 Proteomic Biomarkers
- 6.3 Tumor Mutational Burden (TMB)
- 6.4 PD-L1 Expression
- 6.5 Other Biomarkers

7 GLOBAL PRECISION ONCOLOGY & CANCER IMMUNOTHERAPY MARKET, BY CANCER TYPE

- 7.1 Lung Cancer
- 7.2 Breast Cancer
- 7.3 Colorectal Cancer
- 7.4 Melanoma
- 7.5 Hematologic Cancers
- 7.6 Other Cancer Types

8 GLOBAL PRECISION ONCOLOGY & CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY

- 8.1 Next-Generation Sequencing (NGS)
- 8.2 PCR-Based Testing
- 8.3 Flow Cytometry

8.4 Gene Editing Technologies

8.5 Other Technologies

9 GLOBAL PRECISION ONCOLOGY & CANCER IMMUNOTHERAPY MARKET, BY END USER

9.1 Hospitals

9.2 Cancer Research Institutes

9.3 Specialty Oncology Clinics

9.4 Diagnostic Laboratories

9.5 Other End Users

10 GLOBAL PRECISION ONCOLOGY & CANCER IMMUNOTHERAPY MARKET, BY GEOGRAPHY

10.1 North America

10.1.1 United States

10.1.2 Canada

10.1.3 Mexico

10.2 Europe

10.2.1 United Kingdom

10.2.2 Germany

10.2.3 France

10.2.4 Italy

10.2.5 Spain

10.2.6 Netherlands

10.2.7 Belgium

10.2.8 Sweden

10.2.9 Switzerland

10.2.10 Poland

10.2.11 Rest of Europe

10.3 Asia Pacific

10.3.1 China

10.3.2 Japan

10.3.3 India

10.3.4 South Korea

10.3.5 Australia

10.3.6 Indonesia

10.3.7 Thailand

- 10.3.8 Malaysia
- 10.3.9 Singapore
- 10.3.10 Vietnam
- 10.3.11 Rest of Asia Pacific
- 10.4 South America
 - 10.4.1 Brazil
 - 10.4.2 Argentina
 - 10.4.3 Colombia
 - 10.4.4 Chile
 - 10.4.5 Peru
 - 10.4.6 Rest of South America
- 10.5 Rest of the World (RoW)
 - 10.5.1 Middle East
 - 10.5.1.1 Saudi Arabia
 - 10.5.1.2 United Arab Emirates
 - 10.5.1.3 Qatar
 - 10.5.1.4 Israel
 - 10.5.1.5 Rest of Middle East
 - 10.5.2 Africa
 - 10.5.2.1 South Africa
 - 10.5.2.2 Egypt
 - 10.5.2.3 Morocco
 - 10.5.2.4 Rest of Africa

11 STRATEGIC MARKET INTELLIGENCE

- 11.1 Industry Value Network and Supply Chain Assessment
- 11.2 White-Space and Opportunity Mapping
- 11.3 Product Evolution and Market Life Cycle Analysis
- 11.4 Channel, Distributor, and Go-to-Market Assessment

12 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES

- 12.1 Mergers and Acquisitions
- 12.2 Partnerships, Alliances, and Joint Ventures
- 12.3 New Product Launches and Certifications
- 12.4 Capacity Expansion and Investments
- 12.5 Other Strategic Initiatives

13 COMPANY PROFILES

- 13.1 Roche Holding AG
- 13.2 Bristol-Myers Squibb Company
- 13.3 Merck & Co., Inc.
- 13.4 Novartis AG
- 13.5 Pfizer Inc.
- 13.6 Johnson & Johnson
- 13.7 AstraZeneca plc
- 13.8 Gilead Sciences Inc.
- 13.9 Amgen Inc.
- 13.10 Regeneron Pharmaceuticals
- 13.11 BeiGene Ltd.
- 13.12 Moderna Inc.
- 13.13 BioNTech SE
- 13.14 Iovance Biotherapeutics
- 13.15 Bluebird Bio Inc.
- 13.16 Kite Pharma

List Of Tables

LIST OF TABLES

Table 1 Global Precision Oncology & Cancer Immunotherapy Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Precision Oncology & Cancer Immunotherapy Market, By Therapy Type (2023–2034) (\$MN)

Table 3 Global Precision Oncology & Cancer Immunotherapy Market, By Immune Checkpoint Inhibitors (2023–2034) (\$MN)

Table 4 Global Precision Oncology & Cancer Immunotherapy Market, By CAR-T Cell Therapy (2023–2034) (\$MN)

Table 5 Global Precision Oncology & Cancer Immunotherapy Market, By Cancer Vaccines (2023–2034) (\$MN)

Table 6 Global Precision Oncology & Cancer Immunotherapy Market, By Monoclonal Antibodies (2023–2034) (\$MN)

Table 7 Global Precision Oncology & Cancer Immunotherapy Market, By Targeted Small Molecule Therapy (2023–2034) (\$MN)

Table 8 Global Precision Oncology & Cancer Immunotherapy Market, By Other Therapy Types (2023–2034) (\$MN)

Table 9 Global Precision Oncology & Cancer Immunotherapy Market, By Biomarker (2023–2034) (\$MN)

Table 10 Global Precision Oncology & Cancer Immunotherapy Market, By Genomic Biomarkers (2023–2034) (\$MN)

Table 11 Global Precision Oncology & Cancer Immunotherapy Market, By Proteomic Biomarkers (2023–2034) (\$MN)

Table 12 Global Precision Oncology & Cancer Immunotherapy Market, By Tumor Mutational Burden (TMB) (2023–2034) (\$MN)

Table 13 Global Precision Oncology & Cancer Immunotherapy Market, By PD-L1 Expression (2023–2034) (\$MN)

Table 14 Global Precision Oncology & Cancer Immunotherapy Market, By Other Biomarkers (2023–2034) (\$MN)

Table 15 Global Precision Oncology & Cancer Immunotherapy Market, By Cancer Type (2023–2034) (\$MN)

Table 16 Global Precision Oncology & Cancer Immunotherapy Market, By Lung Cancer (2023–2034) (\$MN)

Table 17 Global Precision Oncology & Cancer Immunotherapy Market, By Breast Cancer (2023–2034) (\$MN)

Table 18 Global Precision Oncology & Cancer Immunotherapy Market, By Colorectal

Cancer (2023–2034) (\$MN)

Table 19 Global Precision Oncology & Cancer Immunotherapy Market, By Melanoma (2023–2034) (\$MN)

Table 20 Global Precision Oncology & Cancer Immunotherapy Market, By Hematologic Cancers (2023–2034) (\$MN)

Table 21 Global Precision Oncology & Cancer Immunotherapy Market, By Other Cancer Types (2023–2034) (\$MN)

Table 22 Global Precision Oncology & Cancer Immunotherapy Market, By Technology (2023–2034) (\$MN)

Table 23 Global Precision Oncology & Cancer Immunotherapy Market, By Next-Generation Sequencing (NGS) (2023–2034) (\$MN)

Table 24 Global Precision Oncology & Cancer Immunotherapy Market, By PCR-Based Testing (2023–2034) (\$MN)

Table 25 Global Precision Oncology & Cancer Immunotherapy Market, By Flow Cytometry (2023–2034) (\$MN)

Table 26 Global Precision Oncology & Cancer Immunotherapy Market, By Gene Editing Technologies (2023–2034) (\$MN)

Table 27 Global Precision Oncology & Cancer Immunotherapy Market, By Other Technologies (2023–2034) (\$MN)

Table 28 Global Precision Oncology & Cancer Immunotherapy Market, By End User (2023–2034) (\$MN)

Table 29 Global Precision Oncology & Cancer Immunotherapy Market, By Hospitals (2023–2034) (\$MN)

Table 30 Global Precision Oncology & Cancer Immunotherapy Market, By Cancer Research Institutes (2023–2034) (\$MN)

Table 31 Global Precision Oncology & Cancer Immunotherapy Market, By Specialty Oncology Clinics (2023–2034) (\$MN)

Table 32 Global Precision Oncology & Cancer Immunotherapy Market, By Diagnostic Laboratories (2023–2034) (\$MN)

Table 33 Global Precision Oncology & Cancer Immunotherapy Market, By Other End Users (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.

I would like to order

Product name: Precision Oncology & Cancer Immunotherapy Market Forecasts to 2034 – Global Analysis By Therapy Type (Immune Checkpoint Inhibitors, CAR-T Cell Therapy, Cancer Vaccines, Monoclonal Antibodies, Targeted Small Molecule Therapy and Other Therapy Types), Biomarker, Cancer Type, Technology, End User and By Geography

Product link: <https://marketpublishers.com/r/PDEF7190BA93EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PDEF7190BA93EN.html>